First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study GroupKenichi Kobayashi, T. Nukiwa, Akira Inoue et al.|Journal of Clinical Oncology|2009Cited by 63
Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.A. Inoue, Kenichi Kobayashi, Makoto Maemondo et al.|Journal of Clinical Oncology|2011Cited by 37
First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study).Yuji Minegishi, Akihiko Gemma, Makoto Maemondo et al.|Journal of Clinical Oncology|2010Cited by 20
9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 studyA. Inoue, T. Nukiwa, Kenichi Kobayashi et al.|European Journal of Cancer Supplements|2009Cited by 15
The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.A. Inoue, T. Nukiwa, Makoto Maemondo et al.|Journal of Clinical Oncology|2010Cited by 1